100 项与 Chaperone Technologies, Inc. 相关的临床结果
0 项与 Chaperone Technologies, Inc. 相关的专利(医药)
2009-02-01·Antimicrobial Agents and Chemotherapy2区 · 医学
Activity of Levofloxacin Alone and in Combination with a DnaK Inhibitor against Gram-Negative Rods, Including Levofloxacin-Resistant Strains
2区 · 医学
Article
作者: Appelbaum, Peter C. ; Credito, Kim ; Koeth, Laura ; Lin, Gengrong ; Sturgess, Michael A.
ABSTRACTSynergy time-kill testing of levofloxacin alone and in combination with CHP-105, a representative DnaK inhibitor, against 50 gram-negative rods demonstrated that 34 of the 50 strains tested showed significant synergy between levofloxacin and CHP-105 after 12 h and 24 h. Fourteen of these 34 organisms were quinolone resistant (levofloxacin MICs of ≥4 μg/ml).
100 项与 Chaperone Technologies, Inc. 相关的药物交易
100 项与 Chaperone Technologies, Inc. 相关的转化医学